Biblio
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
Posterior reversible encephalopathy syndrome (PRES) and myeloma. Leuk Res Rep. 2024;21:100407.
.